Skip to content
Florbetaben f18
Neuraceq (florbetaben f18) is a small molecule pharmaceutical. Florbetaben f18 was first approved as Neuraceq on 2014-03-19.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
Neuraceq
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Florbetaben f-18
Tradename
Company
Number
Date
Products
NEURACEQLife Molecular ImagingN-204677 RX2014-03-19
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
neuraceqNew Drug Application2022-12-07
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent
Expires
Flag
FDA Information
Florbetaben F-18, Neuraceq, Life Molecular
78071352029-03-18DS, DPU-1497
ATC Codes
V: Various drug classes in atc
— V09: Diagnostic radiopharmaceuticals
— V09A: Central nervous system diagnostic radiopharmaceuticals
— V09AX: Other central nervous system diagnostic radiopharmaceuticals in atc
— V09AX06: Florbetaben (18f)
HCPCS
Code
Description
Q9983
Florbetaben f18, diagnostic, per study dose, up to 8.1 millicuries
Clinical
Clinical Trials
26 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Alzheimer diseaseD000544EFO_0000249F0333—1815
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Immunoglobulin light-chain amyloidosisD000075363——1—12
AmyloidosisD000686EFO_1001875E85——1——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Cognitive dysfunctionD060825G31.84—1——34
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
DementiaD003704F031———56
Parkinson diseaseD010300EFO_0002508G201———12
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Multiple myelomaD009101C90.0————11
Primary progressive aphasiaD018888EFO_0009053G31.01————11
Amyotrophic lateral sclerosisD000690EFO_0000253G12.21————11
Motor neuron diseaseD016472EFO_0003782G12.2————11
Spinocerebellar ataxiasD020754————11
Frontotemporal lobar degenerationD057174————11
Temporal lobe epilepsyD004833EFO_0000773————11
AgingD000375GO_0007568R41.81————11
Central nervous system diseasesD002493HP_0002011G96.9————11
Brain diseasesD001927HP_0001298G93.40————11
Show 7 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameFLORBETABEN F18
INNflorbetaben (18f)
Description
Florbetaben ((18)F) is a member of the class of stilbenoids in which the para-hydrogens of stilbene are replaced by methylamino and 2-{2-[2-((18)F)fluoroethoxy]ethoxy}ethoxy) groups. A positron emission tomography imaging ligand for the detection of amyloid aggregation associated with Alzheimer disease. It has a role as a radioactive imaging agent. It is a stilbenoid, a substituted aniline, a secondary amino compound, a (18)F radiopharmaceutical, a polyether and an aromatic ether.
Classification
Small molecule
Drug class—
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CNc1ccc(/C=C/c2ccc(OCCOCCOCC[18F])cc2)cc1
Identifiers
PDB—
CAS-ID902143-01-5
RxCUI1492940
ChEMBL IDCHEMBL566752
ChEBI ID79033
PubChem CID11501341
DrugBankDB09148
UNII IDTLA7312TOI (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 174 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
2 adverse events reported
View more details